Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) traded up 9.2% during trading on Thursday . The stock traded as high as $15.72 and last traded at $15.14. 36,442 shares traded hands during trading, a decline of 56% from the average session volume of 82,304 shares. The stock had previously closed at $13.86.
Gyre Therapeutics Price Performance
The firm’s 50-day simple moving average is $17.68. The stock has a market cap of $1.21 billion, a PE ratio of -0.67 and a beta of 2.13.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
- Five stocks we like better than Gyre Therapeutics
- Investing In Automotive Stocks
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- What Makes a Stock a Good Dividend Stock?
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
